Galectin Therapeutics is working to improve the lives of patients with MASH cirrhosis, fibrosis, and cancer. Learn more about our NAVIGATE clinical study in MASH cirrhosis.
News
-
10/20/25
Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference -
10/07/25
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 -
09/02/25
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Who We Are
Galectin Therapeutics develops novel therapies to improve the lives of patients with chronic liver disease and cancer.
Learn MoreWhat We Do
Galectin’s lead drug, belapectin (GR‑MD‑02), is a carbohydrate-based drug that inhibits the galectin‑3 protein, involved in many inflammatory, fibrotic, and malignant diseases.
Learn MoreWho We Help
The lead development program is in non‑alcoholic steatohepatitis (MASH) cirrhosis, a serious, life‑threatening disease with no current cure.
Learn More